biological source
mouse
conjugate
unconjugated
antibody form
culture supernatant
antibody product type
primary antibodies
clone
CEA31, monoclonal
description
For In Vitro Diagnostic Use in Select Regions (See Chart)
form
buffered aqueous solution
species reactivity
human
packaging
vial of 0.1 mL concentrate (236M-94), vial of 0.5 mL concentrate (236M-95), bottle of 1.0 mL predilute (236M-97), vial of 1.0 mL concentrate (236M-96), bottle of 7.0 mL predilute (236M-98)
manufacturer/tradename
Cell Marque®
technique(s)
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500
isotype
IgG1
control
colon
shipped in
wet ice
storage temp.
2-8°C
visualization
cytoplasmic
Gene Information
human ... CEACAM5(1048)
General description
Anti-CEA is an antibody against carcinoembryonic antigen (CEA), a protein thought to promote tumor development through its role as a cell adhesion molecule. Anti-CEA positivity is seen in adenocarcinomas of many origins, especially colon and lung adenocarcinomas, but is rarely seen in mesothelial cells and mesotheliomas.
Physical form
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
Preparation Note
Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.
Analysis Note
![]() IVD | ![]() IVD | ![]() IVD | ![]() RUO |
Other Notes
CEA Positive Control Slides, Product No. 236S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
Legal Information
Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品?
试试我们的产品选型工具.
法规信息
监管及禁止进口产品
此项目有
V L Go
Cancer, 37(1 suppl), 562-566 (1976-01-01)
Carcinoembryionic antigen (CEA) a glycoprotein extracted from colonic cancer tissue (beta-globulin electrophoretic mobility, sedimentation coefficient 7 to 8S, and mol wt approximately 200,000) can be detected and measured by radioimmunoassay. Clinical evaluations of CEA determination have given the following results:
Julu Bhatnagar et al.
Anticancer research, 22(3), 1849-1857 (2002-08-10)
Although the prognostic value of Carcinoembryonic antigen (CEA) in colorectal cancer follow-up is well known, CEA expression in esophageal cancer is not widely recognized and studies correlating tissue CEA expression in stomach cancers with tumor differentiation have yielded contradictory results.
H Kamino et al.
Cancer, 61(6), 1142-1148 (1988-03-15)
Forty nasopharyngeal carcinomas (NPC) were studied by immunohistochemistry using an antibody to involucrin and the following three keratin antibodies: (1) an antibody to low molecular weight keratin reactive with nonsquamous epithelium, (2) a high molecular weight keratin antibody reactive with
V Tron et al.
Archives of pathology & laboratory medicine, 111(3), 291-293 (1987-03-01)
Immunohistologic markers have been of considerable value in differentiating malignant mesothelioma from adenocarcinoma. Recently, staining for milk-fat globule (MFG) protein has been suggested as a useful diagnostic test for this separation, but subsequent reports have been conflicting, with some authors
J H Lagendijk et al.
Journal of clinical pathology, 52(4), 283-290 (1999-09-04)
To discriminate between adenocarcinomas that are primary to the ovary and metastatic to the ovary, especially of colonic and breast origin, by immunohistochemistry, using stepwise discriminant analysis or a decision tree. 312 routinely processed, formalin fixed tissue specimens were used.
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持


